Rare Disease Track

28th November – 08:30 – 09:45 – Session I
Education Track

Why Should Europe Take a Lead?

Personalised Medicine has become a reality over the last years. The emergence of ‘omics’ and big data has revolutionized healthcare. The approach of PM is already successfully applied in different healthcare areas such as oncology, cardiology, nutrition and for rare diseases. However, health systems across the EU are often still promoting the ‘one-size fits all’ approach, even if it is known that patients do greatly vary in their molecular characteristics and response to drugs and other interventions.

To make use of the full potentials of PM in the next years ahead several challenges need to be addressed such as the integration of big data, patient empowerment, translation of basic to clinical research, bringing the innovation to the market and shaping sustainable healthcare systems.  Can the EU take a lead to ensure rare disease patients have the best treatments?

Chair

Robert Johnstone

Robert Johnstone

Board Member, International Foundation for Integrated Care (IFIC) and European Forum for Good Clinical Practice (EFGCP)

Panel

The added value of the European Union action on rare diseases

 Antoni-Montserrat

Antonio Montserrat

Former Senior Expert on Cancer and Rare Diseases, DG Public Health, European Commission, Brussels, Belgium

Mariangela Pellegrini

Mariangela Pellegrini

ERN Manager on behalf of ERN-EuroBloodNet Coordination Team

Luana Banu

Luana Banu

International Public Affairs Head, Shire International GmbH

Discussion: Q&A